Mylan announced the launch of Azacitidine for Injection, the generic version of Celgene‘s Vidaza Injection

Vidaza Injection is indicated for the treatment of the five French-American-British (FAB) subtypes of myelodysplastic syndrome. Azacitidine, a nucleoside metabolic inhibitor, works by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The cytotoxic effects of azacitidine cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. 

Related Articles

Azacitidine Injection is available as a 100mg/vial strength.

For more information call (800) RX-MYLAN or visit